Impact of Additional Transthoracic Electrical Cardioversion on Cardiac Function and Atrial Fibrillation Recurrence in Patients with Persistent Atrial Fibrillation Who Underwent Radiofrequency Catheter Ablation
Hindawi Publishing Corporation
Cardiology Research and Practice
Volume 2016, Article ID 4139596, 4 pages
http://dx.doi.org/10.1155/2016/4139596
Research Article
Impact of Additional Transthoracic Electrical
Cardioversion on Cardiac Function and Atrial Fibrillation
Recurrence in Patients with Persistent Atrial Fibrillation Who
Underwent Radiofrequency Catheter Ablation
Deguo Wang,1 Fengxiang Zhang,2 and Ancai Wang1
1
Department of Gerontology, Yijishan Hospital of Wannan Medical College, Wuhu 241001, China
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, China
2
Correspondence should be addressed to Deguo Wang;
Received 16 December 2015; Accepted 4 February 2016
Academic Editor: Kai Hu
Copyright © 2016 Deguo Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Backgrounds and Objective. During the procession of radiofrequency catheter ablation (RFCA) in persistent atrial fibrillation
(AF), transthoracic electrical cardioversion (ECV) is required to terminate AF. The purpose of this study was to determine the
impact of additional ECV on cardiac function and recurrence of AF. Methods and Results. Persistent AF patients received extensive
encircling pulmonary vein isolation (PVI) and additional line ablation. Patients were divided into two groups based on whether they
need transthoracic electrical cardioversion to terminate AF: electrical cardioversion (ECV group) and nonelectrical cardioversion
(NECV group). Among 111 subjects, 35 patients were returned to sinus rhythm after ablation by ECV (ECV group) and 76 patients
had AF termination after the ablation processions (NECV group). During the 12-month follow-ups, the recurrence ratio of patients
was comparable in ECV group (15/35) and NECV group (34/76) (44.14% versus 44.74%, 𝑃 = 0.853). Although left atrial diameters
(LAD) decreased significantly in both groups, there were no significant differences in LAD and left ventricular cardiac function
between ECV group and NECV group. Conclusions. This study revealed that ECV has no significant impact on the maintenance
of SR and the recovery of cardiac function. Therefore, ECV could be applied safely to recover SR during the procedure of catheter
ablation of persistent atrial fibrillation.
1. Introduction
Atrial fibrillation (AF) is the most supraventricular arrhythmias which involved 0.4–1% of people in the general population [1]. AF lead to a low quality of life and high risk of
heart failure, stroke, mortality, and rehospitalization [2–4].
Drug therapy is less effective in maintaining sinus rhythm in
40% of all patients [5] with high adverse effects. Nowadays,
left atrial catheter ablation is widely used to treat AF [6, 7].
Pulmonary vein isolation (PVI) and complex fractionated
atrial electrograms (CFAE) ablation are two common strategies to eliminate triggers and arrhythmogenic substrate of AF
[8, 9]. Moreover, additional linear ablation lines, for example,
at the left atrial roof and mitral isthmus, may abolish more
substrate. However, there are considerable amounts of people
who need to receive transthoracic electrical cardioversion
(ECV) to terminate persistent AF even after ablation. It is
not clear whether ECV affect the recovering of cardiac function and reoccurrence of AF after radiofrequency catheter
ablation (RFCA). Therefore, the purpose of this study was to
determine the impact of additional ECV on cardiac function
after RFCA.
2. Methods and Materials
Patients with symptomatic drug-resistant persistent AF who
underwent catheter ablation at our hospitals were included
in this study. Persistent AF is defined as AF which is
sustained beyond seven days, or lasting less than seven days
but necessitating pharmacologic or electrical cardioversion
2
[10]. Transthoracic echocardiography (TTE) was performed
3 times (before and 6 and 12 months after ablation) to
measure conventional parameters and LA function. Ethics
approval of the present study was obtained from the local
review committee, and all patients provided written informed
consent.
Echocardiographic study was performed by an observer
who was blinded to the study design using an IE33 ultrasound machine (PHILIP, USA) with a 2.5 MHz transducer.
Echocardiograms were recorded and analyzed offline using
a customized software package (EchoPAC Systems, PHILIP,
USA).
Extensive encircling pulmonary vein isolation (PVI) was
performed at the atrial interface of the PV-left atrium [11].
A 7.5-Fr irrigation catheter with a 3.5 mm distal electrode
(ThermoCool, Biosense Webster, USA) was used for ablation.
An electroanatomical mapping system (Carto, Biosense
Webster, Diamond Bar, CA, USA) was used to validate that
linear lines were continuous. The endpoint of the extensive
PVI was creation of extensive bidirectional conduction block
from the atrium to the PVs. If AF was sustained after
PVI, additional ablation consisting of linear ablation of the
LA roof, superior vena cava isolation, and/or ablation of
continuous fractionated atrial electrograms was performed.
If AF did not terminate after that additional ablation, SR
was restored by transthoracic electrical cardioversion (100–
200 J). Patients who did not restore SR were excluded from
this study. Patients were then divided into two groups on
the basis of transthoracic electrical cardioversion: electrical
cardioversion (ECV group) and none electrical cardioversion
(NECV group).
After ablation, patients were followed up for 12 months. At
each outpatient visit, a 12-lead electrocardiogram (ECG), 24
hours’ Holter, and echocardiographic study were performed.
ECG and Holter also were done any time the patients
reported palpitations. If the ECG showed any episodes of
AF or any other atrial tachyarrhythmias lasting >30 s during
follow-up, recurrence of AF was diagnosed.
Continuous data are expressed as mean ± SD. Categorical
data are expressed as absolute numbers or percentages. Comparisons between groups were performed using independent
samples t-test, and 𝜒2 test as appropriate. Two-sided 𝑃 < 0.05
was considered significant for all analyses.
3. Results
A total of 111 patients (89 men; age 56±11 years) were included
in this study. Among them, 35 patients were returned to sinus
rhythm after ablation by ECV (ECV group) and 76 patients
had AF termination after the ablation processions (NECV
group). As shown in Table 1, the clinical characteristics of
the patients in the ECV and NECV groups were comparable.
During the 12-month follow-ups, the recurrence ratio of
patients was comparable in ECV group (15/35) and NECV
group (34/76) (44.14% versus 44.74%, 𝑃 = 0.853).
As shown in Figure 1(b), left atrial diameters (LAD) tent
to decrease significantly compared with preablation in both
ECV and NECV groups during the 6 and 12 months’ followups. There were no significant chan (...truncated)